Table 1.
Clinicopathological characteristics based on RRM1 and hENT-1 expression for advanced biliary tract cancer patients
| Characteristics | Total | RRM1 | hENT-1 | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Negative | Positive | P | Negative | Positive | P | ||
| Age | |||||||
| < 58 | 23 (52.27%) | 6 (13.64%) | 17 (38.63%) | 10 (22.73%) | 13 (29.55%) | ||
| ≥ 58 | 21 (47.73%) | 9 (20.45%) | 12 (27.27%) | 0.241 | 8 (18.18%) | 13 (29.55%) | 0.717 |
| Sex | |||||||
| Female | 20 (45.45%) | 9 (20.45%) | 11 (25.00%) | 13 (29.55%) | 7 (15.91%) | ||
| Male | 24 (54.55%) | 6 (13.64%) | 18 (40.91%) | 0.163 | 5 (11.36%) | 19 (43.18%) | 0.003 |
| TNM stage | |||||||
| II-III | 28 (63, 63%) | 11 (25.00%) | 17 (38.63%) | 11 (25.00%) | 17 (38.63%) | ||
| IV | 16 (36.37%) | 4 (9.10%) | 12 (27.27%) | 0.336 | 7 (15.91%) | 9 (20.45%) | 0.772 |
| Tumor types | |||||||
| CC | 20 (45.45%) | 9 (20.45%) | 11 (25.00%) | 0.163 | 10 (22.73%) | 10 (22.73%) | |
| GB | 24 (54.55%) | 6 (13.64%) | 18 (40.91%) | 8 (18.18%) | 16 (36.37%) | 0.263 | |
| Metastasis site | |||||||
| Liver | 25 (56.82%) | 7 (15.91%) | 18 (40.91%) | 0.328 | 7 (15.91%) | 18 (40.91%) | 0.046 |
| Others | 19 (43.18%) | 8 (18.18%) | 11 (25.00%) | 11 (25.00%) | 8 (18.18%) | ||
CC, Cholangiocarcinoma; GB, Gallbladder.